AbCellera Biologics (ABCL) Cash & Equivalents (2020 - 2026)

AbCellera Biologics has reported Cash & Equivalents for 7 years, with the latest figure at $77.1 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Equivalents fell 87.27% year-over-year to $77.1 million; the trailing twelve-month figure through Mar 2026 stood at $77.1 million (down 87.27% YoY), and the FY2025 full-year result was $533.8 million, down 14.67% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $77.1 million, down from $533.8 million in the prior quarter.
• The five-year high for Cash & Equivalents was $886.5 million in Q4 2022, with the low at $77.1 million in Q1 2026.
• Historically, Cash & Equivalents has averaged $489.9 million across 5 years, with a median of $545.7 million in 2022.
• Annual changes were most pronounced in 2024 — Cash & Equivalents surged 369.26% — and 2026, when it plunged 87.27%.
• AbCellera Biologics' Cash & Equivalents stood at $886.5 million in 2022, then slumped by 84.96% to $133.3 million in 2023, then surged by 369.26% to $625.6 million in 2024, then dropped by 14.67% to $533.8 million in 2025, then plunged by 85.56% to $77.1 million in 2026.
• The last three Cash & Equivalents figures came in at $77.1 million (Q1 2026), $533.8 million (Q4 2025), and $495.7 million (Q3 2025), per Business Quant data.